Latent TB Testing Market Size Worth USD 1,005.69 Million by 2034 | CAGR: 5.7%

The latent TB testing market size is expected to reach USD 1,005.69 million by 2034, according to a new study by Polaris Market Research. The report “Latent TB Testing Market Share, Size, Trends, Industry Analysis Report: By Test Type (IGRA and TST), Application, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Latent TB testing refers to diagnostic procedures used to identify tuberculosis (TB) infection in asymptomatic individuals before it progresses to active disease. One of the key latent TB testing market trends is the shift toward high-precision, laboratory-based diagnostics, particularly with the increasing adoption of Interferon-Gamma Release Assays (IGRAs). These advanced testing methods offer improved accuracy and eliminate the need for multiple patient visits, improving compliance and efficiency in large-scale screening programs. Additionally, continuous advancements in molecular diagnostics and automation are streamlining testing workflows, reducing turnaround times, and increasing the reliability of results. The growing demand for such innovations underscores the market’s emphasis on precision and operational efficiency in TB detection.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/latent-tb-testing-market/request-for-sample

Another major trend shaping the latent TB testing market growth is the expansion of preventive screening programs driven by heightened awareness and policy initiatives. Governments, healthcare organizations, and nonprofit entities are actively promoting early detection strategies to curb the global TB burden, particularly in high-risk populations. The integration of TB screening into routine healthcare check-ups, occupational health programs, and immunosuppressive therapy monitoring has accelerated testing adoption. Additionally, strategic collaborations between diagnostic firms and public health agencies are improving accessibility to reliable testing solutions. This increasing focus on preventive care highlights the market’s evolution toward proactive tuberculosis management, reinforcing the critical role of early and accurate diagnosis.

Top of FormLatent TB Testing Market Report Highlights

• In terms of test type, the IGRA segment dominated the latent TB testing market share in 2024, due to its higher accuracy, reliability, and efficiency compared to the traditional Tuberculin Skin Test (TST).
• Based on end user, the hospitals and clinics segment is expected to witness the fastest growth, driven by their role as primary providers for routine screenings and diagnostic services.
• North America dominated the latent TB testing market revenue in 2024, supported by robust healthcare infrastructure, high awareness, and extensive screening programs.
• The Asia Pacific market is projected to experience the fastest market growth, fueled by the rising TB burden and increasing focus on early detection strategies.
• A few global key market players include QIAGEN; Revvity; Beijing Wantai Biopharmaceutical Co., Ltd.; Sanofi; Endo, Inc.; bioMérieux; SD Biosensor, INC.; Lionex GmbH; Serum Institute of India Pvt. Ltd.; ARKRAY, Inc.; Zhi Fei Biological; AID Autoimmun Diagnostika GmbH; Boditech Med Inc.; Oxford Immunotec (PerkinElmer); and Abbott Laboratories.

Polaris Market Research has segmented the latent TB testing market report on the basis of test type, application, end user, and region:

By Test Type Outlook (Volume, Number of Tests in Thousands; Revenue, USD Million, 2020–2034)

• IGRA
• TST

By Application Outlook (Volume, Number of Tests in Thousands; Revenue, USD Million, 2020–2034)

• People Living with HIV
• HHC with TB
• Others

By End User Outlook (Volume, Number of Tests in Thousands; Revenue, USD Million, 2020–2034)

• Diagnostic Laboratories
• Hospitals & Clinics
• Academic & Research Institutes
• Others

By Regional Outlook (Volume, Number of Tests in Thousands; Revenue, USD Million, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Latent TB Testing Market Report Scope